Antitumor activity of cis-dichlorodiammineplatinum(II).
Antitumor activity of cis-dichlorodiammineplatinum(II).
复制标题
顺式二氯二氨铂(II) 的抗肿瘤活性。
DOI：
--
复制
发表时间：
1979
期刊：
影响因子：
--
通讯作者：
M. Wolpert
中科院分区：
文献类型：
--
作者：
M. Wolpert
顺式-二氯二氨铂（II）在目前的癌症治疗部（国家癌症研究所）肿瘤小组中显示出良好的广谱活性。在10种肿瘤系统中至少有5种（ip B16黑色素瘤、sc CD 8 F1乳腺癌、ip结肠肿瘤26、ip L1210白血病和ip P388白血病）中符合活性的决策网络标准。对sc结肠肿瘤38、iv刘易斯肺肿瘤、ic室管膜母细胞瘤和人乳腺肿瘤异种移植物（MX-1）的活性是边缘的。未检测到对人肺肿瘤异种移植物（LX-1）的活性，但观察到对鼠M5076卵巢癌的良好的、可重复的活性。IP给药后未观察到IP L1210白血病的方案依赖性。最近开发的肾包膜下试验提供了一种快速的方法（小于或等于11天）排名的各种人类肿瘤的顺式二氯二氨铂（II）和其他化疗药物的敏感性的承诺。
cis-Dichlorodiammineplatinum(II) has shown good broad-spectrum activity in the current Division of Cancer Treatment (National Cancer Institute) tumor panel. It meets Decision Network criteria for activity in at least five of ten tumor systems (the ip B16 melanoma, the sc CD8F1 mammary carcinoma, the ip colon tumor 26, the ip L1210 leukemia, and the ip P388 leukemia). Activity against the sc colon tumor 38, the iv Lewis lung tumor, the ic ependymoblastoma, and the human breast tumor xenograft (MX-1) was marginal. No activity was detected against the human lung tumor xenograft (LX-1), but good, reproducible activity was observed against the murine M5076 ovarian carcinoma. No schedule-dependency was observed after ip administration against the ip L1210 leukemia. The recently developed subrenal capsule assay offers promise as a rapid way (less than or equal to 11 days) of ranking the sensitivity of a variety of human tumors to cis-dichlorodiammineplatinum(II) and other chemotherapeutic agents.